Shots:
- Amgen to acquire all of the outstanding shares of Five Prime for $38.00 /share in cash, representing an equity value of ~ $1.9B. The transaction is expected to close in Q2’21
- The acquisition will add Five Prime’s innovative pipeline to Amgen thus expanding its oncology portfolio and supports its international expansion strategy
- Five Prime’s bemarituzumab complements Amgen’s oncology portfolio. Bemarituzumab, is a first-in-class, P-III ready anti-FGFR2b Ab that demonstrated improvement in PFS, ORR, OS in the frontline treatment of patients with advanced gastric or GEJ cancer in its P-II study
Click here to read full press release/ article | Ref: PRnewswire | Image: PRNewswire
The post Amgen to Acquire Five Prime for ~$1.9B first appeared on PharmaShots.
